Mercury Laboratories Ltd (MERCURYLAB) — shareholding pattern, promoter holding, financials and share price
About Mercury Laboratories Ltd (MERCURYLAB)
Mercury Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as MERCURYLAB and on the BSE under scrip code 538964. Its ISIN is INE947G01011.
Incorporated in 1962, Mercury Laboratories Ltd manufactures and exports Pharmaceutical items of gyno and pediatrics. [1]
Mercury Laboratories Limited, established in 1962, is a pharmaceutical company specializing in medicinal drugs and formulations. Incorporated as a private limited company in 1982, it later transitioned to a publicly listed entity in 1992.
The company consistently generates profits and pays dividends, indicating robust financial health and shareholder value.
Listed peers in Pharmaceuticals: Sotac Pharmaceuticals Ltd, Par Drugs & Chemicals Ltd, Denis Chem Lab Ltd, Vaishali Pharma Ltd, Concord Drugs Ltd, Makers Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹809 a share on 10 Jul 2026, Mercury Laboratories Ltd (MERCURYLAB) was valued at a price-to-earnings ratio of 20.06x against an industry P/E of 36.41x and a price-to-book of 1.81x on a book value of ₹446.41 per share as of Mar 2025. Solomo computes return on equity of 9.04% and return on capital employed of 12.18% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 20.06x
- Industry P/E
- 36.41x
- P/B
- 1.81x
- EPS (TTM)
- ₹40.33
- Book value / share
- ₹446.41
- ROE
- 9.04%
- ROCE
- 12.18%
- ROA
- 6.52%
- Debt / equity
- 0.1x
- Dividend yield
- 0.43%
- EBITDA margin
- 13.97%
- 52-week range
- ₹620.55 – ₹976
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Mercury Laboratories Ltd (MERCURYLAB) reported revenue of ₹75.94 crore, net profit of ₹4.83 crore and earnings per share of ₹40.25. That compares with revenue of ₹75.1 crore and net profit of ₹3.14 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹20.44 crore and net profit ₹1.23 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 57.92 | 75.33 | 75.56 | 75.1 | 75.94 |
| Net profit (₹ cr) | 3.56 | 5.58 | 5.65 | 3.14 | 4.83 |
| EPS (₹) | 29.67 | 46.5 | 47.08 | 26.17 | 40.25 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 4.70% | 5.57% | 9.04% | -0.61% |
| Profit growth | -2.43% | -0.52% | -4.07% | -44.42% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 73.66% of Mercury Laboratories Ltd (MERCURYLAB) (unchanged from the previous quarter). Market capitalisation was ₹97 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2014.
Largest disclosed public shareholders in Jun 2026: Investor Education And Protection Fund Authority Ministry Of Corporate Affairs 6.4%, Rajeshri Ketan Shah 2.2%, Bharti Bharat Dattani 1.64%, Jeet Ketan Shah 1.31%, Sharad Kanayalal Shah 1.11%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 73.66% | - | - | - | 26.34% |
| Mar 2026 | 73.66% | - | - | - | 26.34% |
| Dec 2025 | 73.66% | - | - | - | 26.34% |
| Sep 2025 | 73.66% | - | - | - | 26.34% |
| Jun 2025 | 73.66% | - | - | - | 26.34% |
| Mar 2025 | 73.66% | - | - | - | 26.34% |
| Dec 2024 | 73.66% | - | - | - | 26.34% |
| Sep 2024 | 73.66% | - | - | - | 26.34% |